Cerebral Infarction Clinical Trial
Official title:
BRUSH Sign: Radiolographic Marker of Cerebral Infarctus Prognosis
| Verified date | March 2018 |
| Source | Groupe Hospitalier Paris Saint Joseph |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
Today the treatment of ischemic stroke in acute phase is based on medicinal or endovascular revascularization. Cerebral MRI sequences help the diagnostic. This procedure uses deoxyhemoglobin as an endogenous tracer. This is also a scorer of cerebral ischemia and the increase lets visualized transcerebral veins in the suffering zone giving a brush aspect. Several studies show the interest of this sign and conclude that deoxyhemoglobin presence is a predictive factor of cerebral ischemia. The aim of the study is to evaluate this brush-sign and correlate it with the prognosis retrospectively.
| Status | Completed |
| Enrollment | 250 |
| Est. completion date | June 30, 2017 |
| Est. primary completion date | April 1, 2017 |
| Accepts healthy volunteers | |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - age>18 years old - hospitalized for cerebral infarction - MCA territory - MRI within 24hours - Sequence of magnetic susceptibility (SWAN) Exclusion Criteria: - Incomplete cerebral infarct - MRI not possible |
| Country | Name | City | State |
|---|---|---|---|
| France | Groupe Hospitalier Paris Saint Joseph | Paris | Ile-de-France |
| Lead Sponsor | Collaborator |
|---|---|
| Groupe Hospitalier Paris Saint Joseph |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | autonomy level | measurement of autonomy level by mRS | Month 3 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT02551003 -
Neuroprotective Effect of Autologous Cord Blood Combined With Therapeutic Hypothermia Following Neonatal Encephalopathy
|
Phase 1/Phase 2 | |
| Completed |
NCT03281590 -
Stroke and Cerebrovascular Diseases Registry
|
||
| Recruiting |
NCT03605381 -
MORbidity PRevalence Estimate In StrokE
|
||
| Completed |
NCT00684515 -
Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017)
|
Phase 2 | |
| Not yet recruiting |
NCT04082091 -
Screening, Early Referral and Lifestyle Tailored E_prescription for Cardiovascular Prevention
|
||
| Completed |
NCT01915368 -
Determining Optimal Post-Stroke Exercise (DOSE)
|
N/A | |
| Terminated |
NCT01684462 -
The Efficacy and Safety Study of ALbumin Therapy in Acute Ischemic Stroke
|
Phase 2 | |
| Completed |
NCT00386191 -
Safety and Efficacy of Clopidogrel for Cerebral Infarction Treatment
|
Phase 4 | |
| Completed |
NCT00004734 -
Vitamin Therapy for Prevention of Stroke
|
Phase 3 | |
| Completed |
NCT02684825 -
Detection of Silent Atrial Fibrillation aFter Ischemic StrOke
|
N/A | |
| Completed |
NCT02248233 -
Nimodipine for Treating Acute Massive Cerebral Infarction
|
Phase 4 | |
| Completed |
NCT02963545 -
TSK (Tryptophan - Serotonin - Kynurenine) Biomarkers Assessment in Stroke
|
N/A | |
| Completed |
NCT02511249 -
Early Determinants of Multidimensional Outcome at School Age After Neonatal Arterial Ischemic Stroke
|
N/A | |
| Completed |
NCT02101606 -
Penumbral Based Novel Thrombolytic Therapy in Acute Ischemic Stroke
|
Phase 2 | |
| Completed |
NCT01500421 -
Safty and Feasibility Study of Therapeutic Cooling in Acute Ischemic Stroke (COOLAID Øresund)
|
Phase 2 | |
| Completed |
NCT00829361 -
Stroke Telemedicine for Arizona Rural Residents Trial
|
N/A | |
| Recruiting |
NCT01003470 -
Treating Apoplectic Sequela With Acupuncture: a Randomized Controlled Study
|
Phase 2 | |
| Terminated |
NCT00331890 -
ICTUS Study: International Citicoline Trial on Acute Stroke
|
Phase 3 | |
| Not yet recruiting |
NCT04696523 -
Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage
|
Phase 2 | |
| Completed |
NCT03741400 -
Virtual Reality Glove for Hand and Arm Rehabilitation After Stroke
|
N/A |